Fennec製藥 FENC 深 滬
已收盤 02-06 16:00:00 美东时间
7.84
+0.180
+2.35%
華盛通- 最 高7.95
- 今 開7.75
- 成交量 9.13万股
- 最 低 7.55
- 昨 收 7.66
- 總市值 2.68亿
- 52周最高 9.92
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 4.68
- 委 比 -25.39%
- 總股本 3415.35万
- 歷史最高 14.986
- 量 比 0.74
- 振 幅 5.22%
- 歷史最低 3.255
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fennec Pharmaceuticals Director Rosty Raykov Reports Disposal of Common Shares
Fennec Pharmaceuticals Director Rosty Raykov Reports Disposal of Common Shares Rosty Raykov, a Director of Fennec Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public T
02-03 05:55
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Piper Sandler Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $18
Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.
01-09 21:22
Southpoint sells $7.5M worth stock of Fennec Pharmaceuticals
Southpoint Capital Advisors, acting on behalf of certain Southpoint funds disposed of beneficial ownership of 1M shares of Fennec Pharmaceuticals (FENC) at a price of $7.50, representing ~2.93% of s...
2025-12-29 13:12
Southpoint Trims Stake in Fennec Pharmaceuticals to 8%
Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. Southpoint Ca...
2025-12-27 07:02
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
Southpoint Capital Advisors LP reported on December 24, 2025, that it disposed of 1,000,000 common shares of Fennec Pharmaceuticals Inc., representing approximately 2.93% of the outstanding shares, at USD$7.50 per share. Southpoint now controls 2.7 million shares, or 8% of the outstanding shares. The sale was made for investment purposes, and Southpoint may adjust its ownership in the future based on market conditions.
2025-12-26 22:44
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
2025-12-03 00:56
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Fennec Pharmaceuticals Inc. announced its participation in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:00 p.m. ET, available via webcast. The webcast can be accessed through the company's investor website, and an archived replay will be provided post-event. Fennec, focused on reducing ototoxicity in cancer patients receiving cisplatin-based chemotherapy, markets PEDMARK, approved in the U.S., E...
2025-11-26 10:59
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
Fennec Pharmaceuticals has repurchased and redeemed all outstanding convertible notes issued to Petrichor funds, totaling $21.73 million, eliminating its debt. The company focuses on PEDMARK® and PEDMARQSI®, which have received regulatory approvals in the U.S., Europe, and the UK. PEDMARQSI® is now available in the UK and Germany under a licensing agreement with Norgine. The products benefit from orphan drug exclusivity and pediatric marketing au...
2025-11-19 12:03
Fennec Pharmaceuticals Reports Increased PEDMARK Sales
Fennec Pharmaceuticals ( ($FENC) ) has released its Q3 earnings. Here is a brea...
2025-11-18 11:53
